Search





Search





Markets
/
Stocks
/
nasdaq-coep
/

Coeptis Therapeutics Holdings Inc

COEP

Add to Watchlist

16.400USD

0.0000.00%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

475.74MMarket Cap

LossP/E TTM



Coeptis Therapeutics Holdings Inc

16.400

0.0000.00%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Coeptis Therapeutics Holdings Inc

Currency: USD Updated: 2026-04-24

Key Insights

Coeptis Therapeutics Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 197 out of 389 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Coeptis Therapeutics Holdings Inc's Score

Industry at a Glance

Industry Ranking

197 / 389

Overall Ranking

369 / 4519

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Coeptis Therapeutics Holdings Inc Highlights

StrengthsRisks

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.36M.

Undervalued

The company’s latest PE is -5.83, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 562.19K shares, increasing 37.66% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 339.49K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-04-24

The current financial score of Coeptis Therapeutics Holdings Inc is 7.37, ranking 96 out of 389 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.37

Change



Financials

8.44

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.76

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.13

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Coeptis Therapeutics Holdings Inc's Company Valuation

Currency: USD Updated: 2026-04-24

The current valuation score of Coeptis Therapeutics Holdings Inc is 5.87, ranking 352 out of 389 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.83, which is -94.00% below the recent high of -0.35 and 0.00% above the recent low of -5.83.

Score

Industry at a Glance

Previous score

5.87

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 197/389

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-04-24

No earnings forecast score is currently available for Coeptis Therapeutics Holdings Inc. The Biotechnology & Medical Research industry's average is 8.08.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-04-24

The current price momentum score of Coeptis Therapeutics Holdings Inc is 9.13, ranking 54 out of 389 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 19.09 and the support level at 11.89, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.24

Change

-0.11

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.938

Buy

RSI(14)

72.101

Buy

STOCH(KDJ)(9,3,3)

86.771

Overbought

ATR(14)

1.174

Low Volatility

CCI(14)

124.393

Buy

Williams %R

12.306

Overbought

TRIX(12,20)

1.219

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

15.636

Buy

MA10

14.407

Buy

MA20

12.876

Buy

MA50

12.260

Buy

MA100

13.278

Buy

MA200

13.579

Buy

Institutional Confidence

Currency: USD Updated: 2026-04-24

The current institutional shareholding score of Coeptis Therapeutics Holdings Inc is 3.00, ranking 197 out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 9.03%, representing a quarter-over-quarter increase of 166.96%. The largest institutional shareholder is The Vanguard, holding a total of 339.49K shares, representing 5.46% of shares outstanding, with 651.18% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Mehalick (David)

330.19K

+153.86%

Calise (Chris)

321.63K

+2.86%

Cogley (Brian)

22.50K

Salkind (Gene)

13.16K

+212.54%

Armistice Capital LLC

94.77K

Deschamps (Philippe)

8.95K

Cochran (Christopher P)

8.95K

Desilva (Tara)

8.95K

Risk Assessment

Currency: USD Updated: 2026-04-24

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Coeptis Therapeutics Holdings Inc is 3.11, ranking 166 out of 389 in the Biotechnology & Medical Research industry. The company's beta value is -0.10. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.